Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration

Thomas A. Ciulla, Philip J Rosenfeld

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

The accumulation of preclinical and clinical evidence implicating VEGF-A in the pathogenesis of neovascular AMD has provided a strong rationale for the development of anti-VEGF agents for this disease. Anti-VEGF therapies have been used successfully in the clinic, encouraging their use in the treatment of other neovascular eye diseases.

Original languageEnglish
Pages (from-to)158-165
Number of pages8
JournalCurrent Opinion in Ophthalmology
Volume20
Issue number3
DOIs
StatePublished - May 1 2009

Fingerprint

Endothelial Growth Factors
Macular Degeneration
Vascular Endothelial Growth Factor A
Eye Diseases
Therapeutics

Keywords

  • Bevacizumab
  • Macular degeneration
  • Neovascularization
  • Pegaptanib sodium
  • Ranibizumab

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. / Ciulla, Thomas A.; Rosenfeld, Philip J.

In: Current Opinion in Ophthalmology, Vol. 20, No. 3, 01.05.2009, p. 158-165.

Research output: Contribution to journalArticle

@article{cdbba3c37d014a8f9ffa8a9dfd588ea0,
title = "Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration",
abstract = "Lippincott Williams & Wilkins.",
keywords = "Bevacizumab, Macular degeneration, Neovascularization, Pegaptanib sodium, Ranibizumab",
author = "Ciulla, {Thomas A.} and Rosenfeld, {Philip J}",
year = "2009",
month = "5",
day = "1",
doi = "10.1097/ICU.0b013e32832d25b3",
language = "English",
volume = "20",
pages = "158--165",
journal = "Current Opinion in Ophthalmology",
issn = "1040-8738",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration

AU - Ciulla, Thomas A.

AU - Rosenfeld, Philip J

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Lippincott Williams & Wilkins.

AB - Lippincott Williams & Wilkins.

KW - Bevacizumab

KW - Macular degeneration

KW - Neovascularization

KW - Pegaptanib sodium

KW - Ranibizumab

UR - http://www.scopus.com/inward/record.url?scp=65549162660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549162660&partnerID=8YFLogxK

U2 - 10.1097/ICU.0b013e32832d25b3

DO - 10.1097/ICU.0b013e32832d25b3

M3 - Article

C2 - 19417570

AN - SCOPUS:65549162660

VL - 20

SP - 158

EP - 165

JO - Current Opinion in Ophthalmology

JF - Current Opinion in Ophthalmology

SN - 1040-8738

IS - 3

ER -